1,343 results on '"Harrison, Claire N."'
Search Results
2. Inherited polygenic effects on common hematological traits influence clonal selection on JAK2V617F and the development of myeloproliferative neoplasms
3. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
4. Treatment and management of myelofibrosis in the era of JAK inhibitors
5. Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms
6. Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies
7. Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib
8. How I treat patients with low-risk polycythemia vera who require cytoreduction
9. Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis
10. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
11. Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
12. Biological drivers of clinical phenotype in myelofibrosis
13. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
14. Essential thrombocythemia: challenges in clinical practice and future prospects
15. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
16. Anemia in myelofibrosis: Current and emerging treatment options
17. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
18. Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice
19. Considerations to comprehensive care for the older individual with myelofibrosis
20. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
21. Clinical utility of investigations in triple‐negative thrombocytosis: A real‐world, multicentre evaluation of UK practice.
22. How I Treat Low-risk Polycythemia Vera Patients who Require Cytoreduction
23. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial
24. Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
25. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
26. Current and future status of JAK inhibitors
27. Identifying disease-modifying potential in myelofibrosis clinical trials
28. Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature
29. A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib:stage 2 of a phase II trial
30. Are we ready for disease modification in myeloproliferative neoplasms?
31. Correction: Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
32. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
33. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
34. Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives
35. Management of myelofibrosis after ruxolitinib failure
36. Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa.
37. Erythrocytosis: Diagnosis and investigation.
38. How I Treat: Myeloproliferative Neoplasms in Pregnancy
39. Longitudinal Safety of Luspatercept in the Treatment of Anemia in Patients with Myelofibrosis: Results from the ACE-536-MF-001 Study
40. Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib
41. Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
42. Thrombocytosis and Essential Thrombocythaemia : Search Strategy and Evidence-Based Diagnosis
43. Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study
44. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
45. SOHO State-of-the-Art Update and Next Questions: MPN
46. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
47. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs
48. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
49. Ruxolitinib for the management of myelofibrosis: Results of an international physician survey
50. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.